Novo Holdings — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
BiotechBoston, US
David Donabedian(Executive Officer, Director)Robert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)Raymond Camahort(Director)
Co-investorsDCVC (Data Collective)DCVC BioLongwood Fund
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)Gregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Co-investorsFemHealth VenturesMitsui Global InvestmentMPM BioImpact
Supira Medical develops a next-generation percutaneous ventricular assist device (pVAD) to provide temporary mechanical circulatory support for high-risk patients undergoing coronary interventions and those in cardiogenic shock.
HardwareHealthtechMedical DevicesCampbell, US
Nitin Salunke(President & CEO)Jean Orth(Executive Officer)Mariam Maghribi(Executive Officer, Director)
BoardCasey Gordon(Director)Christopher Shen(Director)Bihua Chen(Director)
Co-investors415 CapitalAmed VenturesThe Capital PartnershipUnorthodox Ventures
Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.
BiotechHealthtech
Ole Kaasbøll(Co-founder)
Co-investorsHealthCapIndustrifondenLifeArc VenturesInvestinor
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.